Replies to post #64540 on Biotech Values

[quantumdot]

Biotech buyouts. Does Roche's pretty aggressive $3.4 billion swallowing of Ventana qualify for your table? It was finally consummated in Feb 2008 and represented a hefty 73% premium to the share price prior to their first hostile offer last year.

http://www.labtechnologist.com/news/ng.asp?n=82685-roche-ventana-companion-diagnostics-breast-cancer-personalised-medicine